What is the mechanism of action of Avastin (bevacizumab)?

Avastin (bevacizumab) is a monoclonal antibody that specifically inhibits vascular endothelial growth factor (VEGF). VEGF is a key protein involved in angiogenesis, which is the process of new blood vessel formation. In many cancers, elevated levels of VEGF contribute to tumor growth and metastasis by promoting the formation of new blood vessels that supply oxygen and nutrients to the tumor.

By blocking VEGF, Avastin effectively reduces blood supply to tumors, which can slow their growth or even lead to tumor shrinkage. This mechanism of action is particularly beneficial in treating various types of cancer, including colorectal, lung, and breast cancer, as it interferes with the tumor's ability to sustain itself through the formation of new blood vessels.

Understanding the role of VEGF in cancer biology highlights why the inhibition of this factor can be a critical therapeutic strategy in oncology. Consequently, Avastin's action can disrupt the cancer progression and improve patient outcomes when combined with other treatments.